ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02053376
Recruitment Status : Active, not recruiting
First Posted : February 3, 2014
Last Update Posted : April 12, 2018
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Nathan Bahary, MD, University of Pittsburgh

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : January 7, 2018
  Estimated Study Completion Date : August 31, 2018